kynurenine has been researched along with Nerve Pain in 8 studies
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Since chronic painful conditions and depression have common pathophysiological patterns, and the kynurenine signaling pathway is involved in both of them, future clinical studies should aim to have outcomes targeting not only pain, but also functionality, mood changes, and quality of life." | 6.66 | The Role of the Kynurenine Signaling Pathway in Different Chronic Pain Conditions and Potential Use of Therapeutic Agents. ( Candido, KD; Jovanovic, F; Knezevic, NN, 2020) |
| "Since chronic painful conditions and depression have common pathophysiological patterns, and the kynurenine signaling pathway is involved in both of them, future clinical studies should aim to have outcomes targeting not only pain, but also functionality, mood changes, and quality of life." | 2.66 | The Role of the Kynurenine Signaling Pathway in Different Chronic Pain Conditions and Potential Use of Therapeutic Agents. ( Candido, KD; Jovanovic, F; Knezevic, NN, 2020) |
| "Migraine and neuropathic pain are common causes of chronic pain." | 2.52 | Drug targets of migraine and neuropathy: treatment of hyperexcitability. ( Balog, A; Majláth, Z; Tajti, J; Vécsei, L, 2015) |
| "However, the significance of KP in neuropathic pain is still poorly understood." | 1.91 | Effect of pharmacological modulation of the kynurenine pathway on pain-related behavior and opioid analgesia in a mouse model of neuropathic pain. ( Ciapała, K; Ciechanowska, A; Mika, J; Pawlik, K; Rojewska, E, 2023) |
| "OBJECTIVE: Neuropathic pain is regulated by several metabolites of the kynurenine pathway (KYNA-kynurenic acid, and QA-quinolinic acid)." | 1.91 | Nociceptive improvements and kynurenine pathway alterations with diclofenac treatment in a rat model of neuropathic pain created by partial sciatic nerve ligation. ( Debbag, S; Saricaoglu, F; Yalcinkaya, A, 2023) |
| "In this study, we found that neuropathic pain is abrogated when the kynurenine metabolic pathway (KYNPATH) initiated by the enzyme indoleamine 2,3-dioxygenase 1 (IDO1) is ablated pharmacologically or genetically." | 1.72 | Meningeal dendritic cells drive neuropathic pain through elevation of the kynurenine metabolic pathway in mice. ( Alves-Filho, JC; Arruda, LM; Buqui, GA; Cecilio, NT; Cunha, FQ; Cunha, TM; Dagostin, A; Davoli-Ferreira, M; Fernandes Gomes, FI; Fonseca, MD; Gonçalves, WA; Guimarães, RM; Huang, L; Kusuda, R; Leão, RM; Lemos, H; Lopes, AH; Lopes, NP; Maganin, AG; Mauriz Marques, LM; Mellor, A; Mendes, AS; O'Connor, JC; Pacholczyk, G; Sant'Anna, MB; Santana, DA; Santana-Coelho, D; Silva, CE; Silva, RL; Souza, GR; Talbot, J, 2022) |
| "Chronic pain was evaluated by thermal hyperalgesia in Hargreaves test and mechanical allodynia in von Frey test, depressive-like behaviors were evaluated by immobility time in forced swim test and tail suspension test." | 1.48 | Chronic trans-astaxanthin treatment exerts antihyperalgesic effect and corrects co-morbid depressive like behaviors in mice with chronic pain. ( Ding, L; Jiang, X; Jing, C; Liu, F; Pang, C; Yan, Q; Zhang, L, 2018) |
| "l-Kynurenine has antinociceptive effects in acute and inflammatory pain." | 1.39 | The L-kynurenine-probenecid combination reduces neuropathic pain in rats. ( Aguilera, P; Barragán-Iglesias, P; Bravo-Hernández, M; Cervantes-Durán, C; González-Esquivel, DF; Granados-Soto, V; Pérez-Severiano, F; Pineda-Farias, JB; Ríos, C, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 5 (62.50) | 2.80 |
| Authors | Studies |
|---|---|
| Ciapała, K | 2 |
| Mika, J | 2 |
| Rojewska, E | 2 |
| Maganin, AG | 1 |
| Souza, GR | 1 |
| Fonseca, MD | 1 |
| Lopes, AH | 1 |
| Guimarães, RM | 1 |
| Dagostin, A | 1 |
| Cecilio, NT | 1 |
| Mendes, AS | 1 |
| Gonçalves, WA | 1 |
| Silva, CE | 1 |
| Fernandes Gomes, FI | 1 |
| Mauriz Marques, LM | 1 |
| Silva, RL | 1 |
| Arruda, LM | 1 |
| Santana, DA | 1 |
| Lemos, H | 1 |
| Huang, L | 1 |
| Davoli-Ferreira, M | 1 |
| Santana-Coelho, D | 1 |
| Sant'Anna, MB | 1 |
| Kusuda, R | 1 |
| Talbot, J | 1 |
| Pacholczyk, G | 1 |
| Buqui, GA | 1 |
| Lopes, NP | 1 |
| Alves-Filho, JC | 1 |
| Leão, RM | 1 |
| O'Connor, JC | 1 |
| Cunha, FQ | 1 |
| Mellor, A | 1 |
| Cunha, TM | 1 |
| Pawlik, K | 1 |
| Ciechanowska, A | 1 |
| Debbag, S | 1 |
| Yalcinkaya, A | 1 |
| Saricaoglu, F | 1 |
| Jovanovic, F | 1 |
| Candido, KD | 1 |
| Knezevic, NN | 1 |
| Jiang, X | 1 |
| Yan, Q | 1 |
| Liu, F | 1 |
| Jing, C | 1 |
| Ding, L | 1 |
| Zhang, L | 1 |
| Pang, C | 1 |
| Pineda-Farias, JB | 1 |
| Pérez-Severiano, F | 1 |
| González-Esquivel, DF | 1 |
| Barragán-Iglesias, P | 1 |
| Bravo-Hernández, M | 1 |
| Cervantes-Durán, C | 1 |
| Aguilera, P | 1 |
| Ríos, C | 1 |
| Granados-Soto, V | 1 |
| Vécsei, L | 1 |
| Majláth, Z | 1 |
| Balog, A | 1 |
| Tajti, J | 1 |
3 reviews available for kynurenine and Nerve Pain
| Article | Year |
|---|---|
The Kynurenine Pathway as a Potential Target for Neuropathic Pain Therapy Design: From Basic Research to Clinical Perspectives.
Topics: Analgesics; Animals; Biomarkers; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Kynurenine 3-Mono | 2021 |
The Role of the Kynurenine Signaling Pathway in Different Chronic Pain Conditions and Potential Use of Therapeutic Agents.
Topics: Analgesics; Animals; Chronic Pain; Depression; Headache; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenas | 2020 |
Drug targets of migraine and neuropathy: treatment of hyperexcitability.
Topics: Animals; Excitatory Amino Acid Agents; Glutamic Acid; Humans; Hyperalgesia; Kynurenine; Migraine Dis | 2015 |
5 other studies available for kynurenine and Nerve Pain
| Article | Year |
|---|---|
Meningeal dendritic cells drive neuropathic pain through elevation of the kynurenine metabolic pathway in mice.
Topics: Animals; Dendritic Cells; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Metabolic Networks and P | 2022 |
Effect of pharmacological modulation of the kynurenine pathway on pain-related behavior and opioid analgesia in a mouse model of neuropathic pain.
Topics: Analgesia; Analgesics, Opioid; Animals; Kynurenine; Mice; Neuralgia; RNA, Messenger; Tryptophan Oxyg | 2023 |
Nociceptive improvements and kynurenine pathway alterations with diclofenac treatment in a rat model of neuropathic pain created by partial sciatic nerve ligation.
Topics: Animals; Diclofenac; Hyperalgesia; Kynurenine; Neuralgia; Nociception; Rats; Rats, Sprague-Dawley; S | 2023 |
Chronic trans-astaxanthin treatment exerts antihyperalgesic effect and corrects co-morbid depressive like behaviors in mice with chronic pain.
Topics: Analgesics; Animals; Behavior, Animal; Chronic Pain; Cytokines; Depression; Hydroxyindoleacetic Acid | 2018 |
The L-kynurenine-probenecid combination reduces neuropathic pain in rats.
Topics: Animals; Drug Therapy, Combination; Female; Hyperalgesia; Kynurenine; Motor Activity; Neuralgia; Pai | 2013 |